A study from the University of California found that double vaccinated young males aged 12 to 15 without underlying medical conditions are four to six times more likely to be diagnosed with vaccine-related myocarditis than be hospitalized with COVID-19.
While the study is yet to be peer-reviewed, this early data appears to substantiate emerging concerns regarding the safety of mRNA vaccines, such as Pfizer-BioNTech and Moderna, and their potential to cause heart inflammation in young males.
In terms of methodology and design, the study is a retrospective epidemiological assessment that reviewed reports filed with the Vaccine Adverse Event Reporting System (VAERS) between January 1 and June 18 among adolescents aged 12 to 17.
According to the study, which examined reports of stratified cardiac adverse event (CAE) rates, “The rate of CAE is 3.7 to 6.1 times higher than their 120-day COVID-19 hospitalization risk as of August 21, 2021 (7-day hospitalizations 1.5/100k population) and 2.6-4.3-fold higher at times of high weekly hospitalization risk (7-day hospitalizations 2.1/100k), such as during January 2021.”
Boys aged 16 to 17 fared better, but not by much, with the rate of CAE still reaching 2.1 to 3.5 times higher than the 4-month COVID-19 hospitalization risk and 1.5 times to 2.5 times higher at times of high weekly COVID-19 hospitalization.
The researchers say that “This [rate of] incidence exceeds [young males] expected 120-day COVID-19 hospitalization rate at both moderate (August 21, 2021 rates) and high COVID-19 hospitalization incidence.”
Overall, the researchers now estimate that there will be 162.2 cases of myocarditis after two doses of Pfizer-BioNTech for healthy males aged 12 to 15 and 94 cases per million for those aged 16 to 17.
The researchers conclude that additional research into the severity of post-vaccination CAE is warranted. Moreover, they stress that quantifications of the benefits of young boys receiving two vaccines need to be done and weighed with simply allowing this demographic to attain natural immunity to minimize risk from vaccines.
